T. Trarbach

发表

Intratumoral expression profiling of genes involved in angiogenesis in colorectal cancer patients treated with chemotherapy plus the VEGFR inhibitor PTK787/ZK 222584 (vatalanib)

W. Zhang, G. Folprecht, K. Danenberg, 2012, The Pharmacogenomics Journal.

Feasibility of whole-body MR with T2- and T1-weighted real-time steady-state free precession sequences during continuous table movement to depict metastases.

M. Ladd, H. Quick, J. Barkhausen, 2008, Radiology.

Phase I study of the humanized antiepidermal growth factor receptor monoclonal antibody EMD72000 in patients with advanced solid tumors that express the epidermal growth factor receptor.

J. Baselga, F. Rojo, O. Dirsch, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Cetuximab with irinotecan, folinic acid and 5-fluorouracil as first-line treatment in advanced gastroesophageal cancer: a prospective multi-center biomarker-oriented phase II study.

S. Kubicka, P. Galle, F. Lordick, 2011, Annals of oncology : official journal of the European Society for Medical Oncology.

Gefitinib in Combination with Capecitabine as Second-Line Therapy in Patients with Advanced Colorectal Cancer (aCRC): A Phase I/II Study of the Arbeitsgemeinschaft Internistische Onkologie (AIO)

W. Schmiegel, U. Vanhoefer, T. Trarbach, 2010, Oncology Research and Treatment.

Phase I study of matuzumab in combination with 5-fluorouracil, leucovorin and cisplatin (PLF) in patients with advanced gastric and esophagogastric adenocarcinomas

U. Vanhoefer, T. Trarbach, N. Schleucher, 2013, Investigational New Drugs.

Safety, tolerability, and efficacy of the first-in-class antibody IMAB362 targeting claudin 18.2 in patients with metastatic gastroesophageal adenocarcinomas.

F. Lordick, Ö. Türeci, U. Şahin, 2013 .

Tumor vessel stabilization and remodeling by anti-angiogenic therapy with bevacizumab

S. Ergün, T. Trarbach, J. Dürig, 2012, Histochemistry and Cell Biology.

Vascular density analysis in colorectal cancer patients treated with vatalanib (PTK787/ZK222584) in the randomised CONFIRM trials

A. Harris, G. Folprecht, A. Giatromanolaki, 2012, British Journal of Cancer.

Survival of patients with initially unresectable colorectal liver metastases treated with FOLFOX/cetuximab or FOLFIRI/cetuximab in a multidisciplinary concept (CELIM study).

F. Lordick, T. Gruenberger, J. Weitz, 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

Prospective, open, multi-centre phase I/II trial to assess safety and efficacy of neoadjuvant radiochemotherapy with docetaxel and oxaliplatin in patients with adenocarcinoma of the oesophagogastric junction

P. Galle, C. Rödel, T. Trarbach, 2013, BMC Cancer.

Oncogenic RAS simultaneously protects against anti-EGFR antibody-dependent cellular cytotoxicity and EGFR signaling blockade

J. Köhler, M. Schuler, K. Schmid, 2013, Oncogene.

Overexpression of acid sphingomyelinase sensitizes glioma cells to chemotherapy.

T. Trarbach, U. Hengge, E. Gulbins, 2007, Antioxidants & redox signaling.

Predictive Biomarkers and Personalized Medicine Prognostic and Predictive Role of Lactate Dehydrogenase 5 Expression in Colorectal Cancer Patients Treated with PTK 787 / ZK 222584 ( Vatalanib ) Antiangiogenic Therapy

A. Harris, G. Folprecht, K. Gatter, 2011 .

Dose escalating study of cetuximab and 5-FU/folinic acid (FA)/oxaliplatin/irinotecan (FOLFOXIRI) in first line therapy of patients with metastatic colorectal cancer

G. Folprecht, T. Trarbach, G. Ehninger, 2014, BMC Cancer.

Interdisciplinary management of EGFR-inhibitor-induced skin reactions: a German expert opinion.

A. Hauschild, H. Lipp, F. Lordick, 2011, Annals of oncology : official journal of the European Society for Medical Oncology.

Maintenance strategies after first-line oxaliplatin plus fluoropyrimidine plus bevacizumab for patients with metastatic colorectal cancer (AIO 0207): a randomised, non-inferiority, open-label, phase 3 trial.

A. Hinke, A. Tannapfel, T. Trarbach, 2015, The Lancet. Oncology.

Prognostic value of KRAS mutations in stage III colon cancer: post hoc analysis of the PETACC8 phase III trial dataset.

R. Greil, B. Chauffert, S. Barni, 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

Randomized, placebo-controlled, phase III study of first-line oxaliplatin-based chemotherapy plus PTK787/ZK 222584, an oral vascular endothelial growth factor receptor inhibitor, in patients with metastatic colorectal adenocarcinoma.

D. Kerr, J. Hainsworth, J. Hecht, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Rectal cancer and synchronous metastases: resection of primary tumor or not?

T. Trarbach, H. Schmoll, 2009, Gastroenterologie clinique et biologique.

Adjuvant chemoradiation using 5-fluorouracil/folinic acid/cisplatin with or without paclitaxel and radiation in patients with completely resected high-risk gastric cancer: two cooperative phase II studies of the AIO/ARO/ACO.

C. Bokemeyer, L. Kanz, U. Vanhoefer, 2005, Annals of oncology : official journal of the European Society for Medical Oncology.

Operations for intrahepatic cholangiocarcinoma: single-institution experience of 158 patients.

T. Trarbach, K. Schmitz, H. Baba, 2009, Journal of the American College of Surgeons.

Safety distance in the resection of colorectal lung metastases: a prospective evaluation of satellite tumor cells with immunohistochemistry.

M. Tötsch, T. Trarbach, D. Theegarten, 2011, The Journal of thoracic and cardiovascular surgery.

A randomized, double-blind, placebo-controlled, phase III study in patients (Pts) with metastatic adenocarcinoma of the colon or rectum receiving first-line chemotherapy with oxaliplatin/5-fluorouracil/leucovorin and PTK787/ZK 222584 or placebo (CONFIRM-1)

J. Hainsworth, J. Hecht, R. Wolff, 2005 .

[Interdisciplinary management of cutaneous adverse events of EGFR inhibitors and multityrosine kinase inhibitors in oncology].

D. Schadendorf, M. Schuler, T. Trarbach, 2011, Deutsche medizinische Wochenschrift.

Ten‐year survival of esophageal cancer after an en‐bloc esophagectomy

T. Trarbach, W. Niebel, A. Paul, 2012, Journal of surgical oncology.

Evaluation of different protocols for gene transfer into non-obese diabetes/severe combined immunodeficiency disease mouse repopulating cells

T. Trarbach, S. Seeber, T. Moritz, 2007, Journal of Cancer Research and Clinical Oncology.

Optimized retroviral transduction protocol for human progenitor cells utilizing fibronectin fragments.

A. Elmaagacli, T. Trarbach, S. Seeber, 2000, Cytotherapy.

Four consecutive multicenter phase II trials of adjuvant chemoradiation in patients with completely resected high-risk gastric cancer: the experience of the German AIO/ARO/CAO group

C. Bokemeyer, T. Trarbach, K. Oechsle, 2009, Journal of Cancer Research and Clinical Oncology.

Quality of life assessment in patients with metastatic colorectal cancer receiving maintenance therapy after first-line induction treatment: a preplanned analysis of the phase III AIO KRK 0207 trial.

A. Hinke, H. Schmoll, A. Tannapfel, 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

Biweekly Cetuximab Plus FOLFOX6 as First-Line Therapy in Patients With RAS Wild-Type Metastatic Colorectal Cancer: The CEBIFOX Trial.

M. Schuler, K. Schmid, K. Worm, 2020, Clinical colorectal cancer.

A meta-analysis of two randomized, double-blind, placebo-controlled, phase III studies in patients (pts) with metastatic colorectal cancer (mCRC) receiving FOLFOX4 and PTK/ZK to determine clinical benefit on progression-free survival (PFS) in high LDH pts.

D. Kerr, E. Van Cutsem, J. Douillard, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase I/II study of PTK787/ZK 222584 (PTK/ZK), a novel, oral angiogenesis inhibitor in combination with FOLFIRI as first-line treatment for patients with metastatic colorectal cancer.

U. Vanhoefer, D. Lebwohl, T. Trarbach, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Expanded phase I/II study of PTK787/ZK 222584 (PTK/ZK), a novel, oral angiogenesis inhibitor, in combination with FOLFOX-4 as first-line treatment for patients with metastatic colorectal cancer.

U. Vanhoefer, B. Wiedenmann, D. Lebwohl, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Use of intratumoral mRNA expression of genes involved in angiogenesis and HIF1 pathway to predict outcome to VEGFR tyrosine kinase inhibitor (TKI) in patients enrolled in CONFIRM1 and CONFIRM2

J. Barrett, G. Folprecht, P. Wilson, 2008 .

A phase II study of the anti-IGFR antibody MK-0646 in combination with cetuximab and irinotecan in the treatment of chemorefractory metastatic colorectal cancer.

F. J. Ramos, D. Cunningham, H. Schmoll, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Gemcitabine and oxaliplatin (GEMOX) alone or in combination with cetuximab as first-line treatment for advanced biliary cancer: Final analysis of a randomized phase II trial (BINGO).

J. Pignon, M. Ducreux, T. Greten, 2012 .

A randomized phase II/III study of the anti-IGF-1R antibody MK-0646 (dalotuzumab) in combination with cetuximab (Cx) and irinotecan (Ir) in the treatment of chemorefractory metastatic colorectal cancer (mCRC) with wild-type (wt) KRAS status.

F. J. Ramos, D. Cunningham, H. Schmoll, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Depth of response of induction therapy and consecutive maintenance treatment in patients with RAS wild-type metastatic colorectal cancer: An analysis of the PanaMa trial (AIO KRK 0212).

V. Heinemann, T. Trarbach, S. Kasper, 2022, European journal of cancer.

Etoposide toxicity on human neuroblastoma cells in vitro is enhanced by preceeding hyperthermia.

T. Trarbach, B. Kremens, R. van Heek-Romanowski, 2001, Medical and pediatric oncology.

A multicenter, randomized phase II trial of gemcitabine and oxaliplatin (GEMOX) alone or in combination with biweekly cetuximab in the first-line treatment of advanced biliary cancer: Interim analysis of the BINGO trial.

T. Greten, E. Assenat, T. Trarbach, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Cetuximab with irinotecan/NA-FA/5-FU as first-line treatment in advanced gastric cancer: Preliminary results of a non-randomised multi-centre AIO phase II study

S. Kubicka, P. Galle, F. Lordick, 2008 .

Novel Prognostic Scoring System after Surgery for Klatskin Tumor

G. Gerken, T. Trarbach, H. Baba, 2013, The American surgeon.

Phase II trial of mapatumumab, a fully human agonistic monoclonal antibody that targets and activates the tumour necrosis factor apoptosis-inducing ligand receptor-1 (TRAIL-R1), in patients with refractory colorectal cancer

V. Heinemann, C. Köhne, T. Trarbach, 2010, British Journal of Cancer.

Molecular dissection of effector mechanisms of RAS-mediated resistance to anti-EGFR antibody therapy

M. Schuler, K. Schmid, K. Worm, 2017, Oncotarget.

Prognostic and Predictive Role of Lactate Dehydrogenase 5 Expression in Colorectal Cancer Patients Treated with PTK787/ZK 222584 (Vatalanib) Antiangiogenic Therapy

A. Harris, G. Folprecht, K. Gatter, 2011, Clinical Cancer Research.

Dose-escalated radiotherapy with PET/CT based treatment planning in combination with induction and concurrent chemotherapy in locally advanced (uT3/T4) squamous cell cancer of the esophagus: mature results of a phase I/II trial

K. Jöckel, T. Gauler, K. Herrmann, 2021, Radiation Oncology.

An open-label, multicentre biomarker-oriented AIO phase II trial of sunitinib for patients with chemo-refractory advanced gastric cancer.

F. Lordick, T. Trarbach, J. Hartmann, 2011, European journal of cancer.

A phase IB, open-label dose-escalating study of the oral angiogenesis inhibitor PTK787/ZK 222584 (PTK/ZK), in combination with FOLFOX4 chemotherapy in patients with advanced colorectal cancer.

U. Vanhoefer, B. Wiedenmann, T. Trarbach, 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

Gemcitabine and oxaliplatin with or without cetuximab in advanced biliary-tract cancer (BINGO): a randomised, open-label, non-comparative phase 2 trial.

J. Pignon, M. Ducreux, T. Greten, 2014, The Lancet. Oncology.

An open-label, multicenter phase II trial of sunitinib for patients with chemorefractory metastatic gastric cancer.

M. Ebert, P. Galle, F. Lordick, 2010 .

Surgical treatment of Klatskin tumor: liver resection versus transplantation.

G. Gerken, T. Trarbach, H. Baba, 2010, Hepato-gastroenterology.

Tumor markers as a diagnostic key for hilar cholangiocarcinoma

B. Juntermanns, T. Trarbach, H. Reis, 2010, European journal of medical research.

Tumor vessel stabilization and remodeling by anti-angiogenic therapy with bevacizumab

S. Ergün, T. Trarbach, J. Dürig, 2012, Histochemistry and Cell Biology.

Doxorubicin enhances TRAIL-induced cell death via ceramide-enriched membrane platforms

T. Trarbach, U. Hengge, E. Gulbins, 2007, Apoptosis.

A phase III, open label, randomized multicenter controlled trial of oral versus intravenous treosulfan in heavily pretreated recurrent ovarian cancer: a study of the North-Eastern German Society of Gynecological Oncology (NOGGO)

M. Lux, I. Runnebaum, T. Trarbach, 2016, Journal of Cancer Research and Clinical Oncology.

Survival of Patients with Synchronous and Metachronous Colorectal Liver Metastases—is there a Difference?

T. Trarbach, E. Molmenti, C. Broelsch, 2008, Journal of Gastrointestinal Surgery.

A randomized phase II study of paclitaxel alone versus paclitaxel plus sorafenib in second- and third-line treatment of patients with HER2-negative metastatic breast cancer (PASO)

T. Decker, T. Trarbach, M. Indorf, 2017, BMC Cancer.

Consensus Molecular Subtypes as Biomarkers of Fluorouracil and Folinic Acid Maintenance Therapy With or Without Panitumumab in RAS Wild-Type Metastatic Colorectal Cancer (PanaMa, AIO KRK 0212)

V. Heinemann, T. Trarbach, S. Kasper, 2023, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Quality of life in pre- and postmenopausal patients with early breast cancer: a comprehensive analysis from the prospective MaLife project

T. Trarbach, N. Marschner, D. Meyer, 2019, Breast Cancer Research and Treatment.

Phase I open-label study of cediranib, an oral inhibitor of VEGF signalling, in combination with the oral Src inhibitor saracatinib in patients with advanced solid tumours

T. Gauler, J. Drevs, T. Trarbach, 2012, Investigational New Drugs.

Prognostic impact of intrahepatic lymphatic and microvascular involvement in cases of colorectal liver metastases

T. Trarbach, S. Sheu, E. Molmenti, 2009, International Journal of Colorectal Disease.

Gemcitabine-Containing Chemotherapy in the Treatment of Patients with Advanced Soft Tissue Sarcoma

T. Gauler, T. Trarbach, S. Seeber, 2002 .

A randomized phase II study of paclitaxel alone versus paclitaxel plus sorafenib in second- and third-line treatment of patients with HER2-negative metastatic breast cancer (PASO)

T. Decker, T. Trarbach, M. Indorf, 2017, BMC Cancer.

636PEFFICACY AND SAFETY OF MULTIPLE DOSES OF IMAB362 IN PATIENTS WITH ADVANCED GASTRO-ESOPHAGEAL CANCER: RESULTS OF A PHASE II STUDY.

Georg von Wichert, F. Lordick, Ö. Türeci, 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

Cetuximab with irinotecan/folinic acid/5-FU as first-line treatment in advanced gastric cancer: A nonrandomized multicenter AIO phase II study.

S. Kubicka, F. Lordick, T. Seufferlein, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Cetuximab and chemotherapy in the treatment of patients with initially “nonresectable” colorectal (CRC) liver metastases: Long-term follow-up of the CELIM trial.

F. Lordick, T. Gruenberger, J. Weitz, 2013 .

Development and validation of a novel prognostic score to predict survival in patients with metastatic colorectal cancer: the metastatic colorectal cancer score (mCCS)

W. Vach, T. Trarbach, M. Frank, 2019, Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland.

Dose escalating study of 5-FU/folinic acid (FA)/oxaliplatin/irinotecan (FOLFOXIRI) and cetuximab in first-line therapy of patients with metastatic colorectal cancer.

G. Folprecht, T. Trarbach, G. Ehninger, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[Specific treatment situations in metastatic colorectal cancer].

H. Amthauer, T. Seufferlein, W. Knoefel, 2010, Onkologie.

Impact of sex on the efficacy and safety of panitumumab plus fluorouracil and folinic acid versus fluorouracil and folinic acid alone as maintenance therapy in RAS WT metastatic colorectal cancer (mCRC). Subgroup analysis of the PanaMa-study (AIO-KRK-0212)

V. Heinemann, T. Trarbach, K. Caca, 2023, ESMO open.

Optimal maintenance strategy following FOLFOX plus anti-EGFR induction therapy in patients with RAS wild type metastatic colorectal cancer: An individual patient data pooled analysis of randomised clinical trials.

T. Trarbach, H. Wasan, E. Díaz-Rubio, 2023, European journal of cancer.

Panitumumab Plus Fluorouracil and Folinic Acid Versus Fluorouracil and Folinic Acid Alone as Maintenance Therapy in RAS Wild-Type Metastatic Colorectal Cancer: The Randomized PANAMA Trial (AIO KRK 0212)

V. Heinemann, T. Trarbach, S. Kasper, 2021, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Quality of life in pre- and postmenopausal patients with early breast cancer: a comprehensive analysis from the prospective MaLife project

T. Trarbach, N. Marschner, D. Meyer, 2019, Breast Cancer Research and Treatment.

V. Heinemann, T. Trarbach, S. Kasper, 2023, European journal of cancer.

[Laparoscopic surgery and adjuvant therapy for colon cancer].

S. Kubicka, H. Bruch, T. Trarbach, 2009, Onkologie.

A phase I, open-label, multicenter study of cediranib and AZD0530 in patients with advanced solid tumors

T. Gauler, J. Drevs, T. Trarbach, 2008 .

Phase I study of the humanized anti-epidermal growth factor receptor (EGFR) antibody EMD 72000 (matuzumab) in combination with cisplatin, 5-fluorouracil and leucovorin (PFL) in patients (pts) with advanced esophago-gastric (EG) adenocarcinoma

U. Vanhoefer, T. Trarbach, S. Seeber, 2005 .

Lenalidomide plus dexamethasone for patients with relapsed or refractory multiple myeloma: Final results of a non-interventional study and comparison with the pivotal phase 3 clinical trials.

T. Trarbach, W. Knauf, J. Mittermueller, 2018, Leukemia research.

Quality of life in patients with metastatic colorectal cancer receiving maintenance therapy after first-line inductive treatment: A quality of life sub-analysis of the AIO KRK 0207 phase III trial

A. Hinke, H. Schmoll, A. Tannapfel, 2016 .

3518 POSTER Cetuximab with Irinotecan/FA/5-FU as first-line treatment in advanced gastric cancer: Preliminary results of a non-randomized multicenter AIO phase II study

S. Kubicka, P. Galle, F. Lordick, 2007 .

Prognostic and Predictive Role of Lactate Dehydrogenase 5 Expression in Colorectal Cancer Patients Treated with PTK787/ZK 222584 (Vatalanib) Antiangiogenic Therapy

A. Harris, G. Folprecht, K. Gatter, 2011, Clinical Cancer Research.

ERCC-1 gene expression levels and outcome to FOLFOX chemotherapy in patients enrolled in CONFIRM1 and CONFIRM2

J. Barrett, H. Lenz, G. Folprecht, 2008 .

Prognostic and predictive impact of metastatic organ involvement on maintenance therapy in advanced metastatic colorectal cancer: Subgroup analysis of patients treated within the PanaMa trial (AIO KRK 0212)

T. Trarbach, S. Haas, E. Goekkurt, 2023, International journal of cancer.

Checkpoint Inhibitor Monotherapy in Potentially Trial-Eligible or Trial-Ineligible Patients With Metastatic NSCLC in the German Prospective CRISP Registry Real-World Cohort (AIO-TRK-0315)

C. Kortsik, T. Trarbach, W. Brueckl, 2023, JTO clinical and research reports.